Unlucky 13: Top Clinical Trial Failures of 2017
In Missing Their Primary Endpoints, These Drugs Sparked Layoffs, Losses, and a CEO Resignation
Top 10 Best-Selling Cancer Drugs, Q1–Q3 2017
15% Year-Over-Year Growth, with Sales Set to More than Double by 2022
Biomaterials Could Extend the Success of Immunotherapies
A New Review Paper Encourages Clinicians to Pull Ideas from the Desks of Engineers
Epigenetic Drugs: Team Players in Combo Therapies
Scientists May Be Better Able to Destroy Tumors and Possibly Reverse CNS Decline
The views, opinions, findings, conclusions, and recommendations set forth in any article in Genetic Engineering & Biotechnology News (GEN) are solely those of the authors of those articles and do not necessarily reflect the views, policy, or position of GEN, its Publisher, or its editorial staff and should not be attributed to any of them.
All advertisements are subject to review by the Publisher. The acceptance of advertisements does not constitute an endorsement of the product or service advertised.
The entire website is the property of Genetic Engineering & Biotechnology News. All rights reserved. Any unauthorized reproduction or redistribution of the website is strictly prohibited. You must obtain permission before using trademarks of Genetic Engineering & Biotechnology News. Any other trademarks or logos appearing on our website are the property of their respective owners.
Hyperlinks to Third Party Sites
This website may contain hyperlinks to third-party websites. Such hyperlinks are provided for reference by and convenience of website users. Genetic Engineering & Biotechnology News is not responsible for the content on third-party websites. Our inclusion of hyperlinks our website does not imply endorsement of the linked website or the company that maintains it.